Neurocrine restructures Takeda deal for osavampator; gets global rights ex-Japan

NEUROCRINE BIOSCIENCES INC

Neurocrine obtains exclusive worldwide development/commercialisation rights for osavampator except Japan, converts from profit-sharing to royalty-bearing license.
Takeda reacquires exclusive rights in Japan; royalties payable by each party on net sales in other's territory.
Tiered royalties to Takeda: mid-to-upper teens (US), low double-digits (ex-US) as % of net sales.
Phase 3 program for major depressive disorder expected to start H1 2025 after successful End-of-Phase 2 FDA meeting.
Amended agreement dated January 24, 2025; press release issued January 27, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.